Skip to content

Cohort Study of Patients with Hereditary Diffuse Leukoencephalopathy with Spheroids After Hematopoietic Stem Cell Transplantation

Cohort Study of Patients with Hereditary Diffuse Leukoencephalopathy with Spheroids After Hematopoietic Stem Cell Transplantation

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061121
Enrollment
Unknown
Registered
2022-06-15
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hereditary Diffuse Leukoencephalopathy with Spheroids

Interventions

Case series:None

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Diagnosed as hereditary diffuse leukoencephalopathy with spheroids as defined by: (1) at least two of the following clinical symptoms and signs: cognitive impairment; psychiatric disorders; pyramidal involvement; parkinsonism; epilepsy; (2) autosomal dominant inheritance or sporadic inheritance; (3) cerebral CT or MRI showed bilateral white matter lesions; (4) with CSF1R gene mutation rated as "pathogenic" or "likely pathogenic"; or the ACMG rating was "uncertain significant" but brain biopsy showed diffuse white matter lesions with axonal spheroids and/or pigment glial cells; or the pathogenicity of the mutation had been verified by well-established in vivo or in vitro functional studies; (5)exclude other causes of white matter lesions (vascular dementia, multiple sclerosis, leukodystrophy, etc.); 2. Aged >= 18 years old and <= 60 years old, male or female; 3. Informed consent was obtain from the subject or a guardian with legal capacity if the subject has no or limited capacity; 4. Has received hematopoietic stem cell transplantation.

Exclusion criteria

Exclusion criteria: 1. Age of onset <= 10 years; 2. In addition to epilepsy, experienced stroke-like episodes at least 2 times; 3. With prominent manifestations of peripheral neuropathy; 4. Pregnant or lactating females, or males or females of childbearing age who are considering bearing recently; 5. Any condition that make it impossible for MRI examination (such as: need to be sedated to carry out MRI examination, but allergic to sedatives, etc.); 6. Receipt of an investigational study drug or procedure within 1 year.

Design outcomes

Primary

MeasureTime frame
progression-free survival;

Countries

China

Contacts

Public ContactLi Cao
caoli@rjlab.cn+86 13472610202

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026